An Inflammation-Targeted Lipid Nanoparticle System for EPO mRNA Delivery in Spinal Cord Injury Repair

Study Background and Research Question

Spinal cord injury (SCI) frequently leads to irreversible neurological deficits due to an initial insult followed by a complex secondary phase characterized by inflammation, neuronal apoptosis, and ferroptosis—a distinct form of iron-dependent cell death. Conventional therapies for SCI have struggled to achieve targeted delivery and sustained bioactivity, limiting their clinical translation. Erythropoietin (EPO), well-recognized for its role in erythropoiesis, has emerged as a promising candidate for neuroprotection due to its anti-inflammatory, anti-apoptotic, and—recently discovered—anti-ferroptotic properties. However, effective translation of EPO into SCI therapy has been hindered by poor accumulation at lesion sites and systemic off-target effects. The central research question addressed by the reference study is: can an engineered mRNA delivery system achieve targeted, localized EPO protein expression at SCI sites to modulate neuroinflammation and ferroptosis, thereby improving functional recovery?

Key Innovation from the Reference Study

The authors introduce a rationally designed, mannose-modified lipid nanoparticle (MLNP) system for the precise delivery of human erythropoietin mRNA (EPO mRNA) to CD206-enriched inflammatory macrophages and microglia within the injured spinal cord. This bioresponsive nanocarrier—termed EPO@MLNP—combines selective targeting, high mRNA encapsulation efficiency, and enhanced stability. By exploiting the mannose receptor-mediated uptake characteristic of inflammatory macrophages, the MLNPs preferentially accumulate at SCI lesions, enabling sustained local translation of therapeutic EPO protein without the off-target risks of recombinant EPO administration. This approach represents a significant advance over prior non-targeted mRNA or protein therapies, directly addressing the spatial and temporal limitations of EPO delivery in neural tissue according to the reference study.

Methods and Experimental Design Insights

The study leveraged a rigorous multi-step experimental design:

• Mannose-functionalized lipid nanoparticles were synthesized and characterized for size, charge, and stability.
• Human erythropoietin mRNA was in vitro transcribed and encapsulated within the MLNPs. Encapsulation efficiency, mRNA integrity, and release kinetics were systematically evaluated.
• Targeting efficacy was validated in vitro using CD206-positive macrophage models, confirming selective uptake and EPO protein expression.
• In vivo, a mouse model of SCI was established. EPO@MLNPs were administered systemically, and nanoparticle biodistribution, retention at the lesion site, and sustained local EPO production were assessed.
• Therapeutic outcomes were measured via neuroinflammation (cytokine profiling), ferroptosis markers (iron metabolism and lipid peroxidation analyses), neuronal loss quantification, axonal integrity, and motor functional recovery (behavioral assays).
• Transcriptomic profiling and targeted validation experiments clarified the mechanism of ferroptosis suppression and neuroprotection.

This comprehensive workflow enabled the authors to dissect both the delivery mechanism and the biological impact of targeted EPO mRNA therapy in SCI contexts.

Core Findings and Why They Matter

EPO@MLNPs demonstrated several key outcomes:

• Targeted Delivery: MLNPs selectively accumulated in SCI lesions, with efficient uptake by inflammatory macrophages/microglia, leading to robust, localized EPO protein synthesis.
• Neuroinflammation Reduction: EPO mRNA treatment significantly decreased pro-inflammatory cytokine expression (including TNF-α, IL-1β, and IL-6), limiting secondary tissue damage.
• Suppression of Ferroptosis: Integrated transcriptomics and biochemical assays confirmed that EPO@MLNPs modulate iron metabolism and reduce lipid peroxidation, thereby inhibiting ferroptosis. Upregulation of anti-ferroptotic regulators such as GPX4 was observed.
• Neuroprotection and Functional Recovery: Treated mice exhibited reduced neuronal loss, preserved serotonergic axonal integrity, and markedly improved motor function compared to controls.

By achieving precise, sustained EPO expression at the injury site, this approach overcomes the limitations of systemic EPO delivery. The dual modulation of inflammation and ferroptosis aligns with the pathological complexity of SCI, offering a synergistic strategy for tissue preservation and functional restoration. These results suggest broad potential for mRNA for erythropoiesis research and neurorepair, and may inform the development of mRNA for gene therapy applications in other neuroinflammatory diseases as well.

Comparison with Existing Internal Articles

Several internal resources provide complementary perspectives on targeted EPO mRNA delivery strategies:

• The article "Targeted EPO mRNA Nanoparticles Suppress Ferroptosis in SCI Repair" similarly describes the use of inflammation-targeted lipid nanoparticles for localized EPO mRNA delivery, corroborating the core findings of reduced neuroinflammation and improved motor function.
• Another internal report expands on mannose-modified nanoparticles as vectors for mRNA for protein expression studies in the context of neurorepair, confirming the potential of this approach for precise immune cell targeting.
• Recent workflow-focused resources discuss experimental strategies and troubleshooting for maximizing EPO mRNA performance in mammalian systems, with particular attention to mRNA stability enhancement and reproducibility.

Together, these articles reinforce the translational potential of inflammation-targeted mRNA delivery for SCI and highlight the practical considerations for robust mRNA-based interventions.

Limitations and Transferability

While the reference study demonstrates compelling efficacy in murine SCI models, several limitations should be considered:

• Preclinical Scope: Findings are restricted to rodent models; human translation will require further validation of safety, immunogenicity, and efficacy in larger animals and clinical trials.
• Nanoparticle Design Complexity: The synthesis and characterization of mannose-modified lipid nanoparticles require specialized expertise and infrastructure, potentially impacting scalability.
• Long-term Outcomes: The durability of neuroprotection and functional recovery over extended periods remains to be established.
• Targeting Specificity: Although CD206-targeting enhances selectivity, off-target effects and distribution in non-inflamed tissues must be systematically evaluated.

Despite these caveats, the approach provides a robust framework for developing mRNA for protein expression studies targeting other neuroinflammatory or ferroptosis-linked conditions.

Protocol Parameters

• EPO mRNA encapsulation: Optimize MLNP:mRNA mass ratio to ensure high encapsulation efficiency and nanoparticle stability.
• In vivo dosing: For murine SCI models, administer EPO@MLNPs intravenously at doses validated for lesion accumulation and safety (precise values should be determined empirically).
• mRNA stability: Use IVT mRNA with poly(A) tail and 5' Cap 1 modification to maximize translational efficiency and minimize innate immune activation.
• Storage and handling: Store mRNA formulations at or below -40°C, aliquot to avoid freeze-thaw cycles, and use RNase-free consumables for all procedures.

Research Support Resources

Researchers aiming to replicate or extend this work may benefit from high-quality in vitro transcribed mRNA reagents. EZ Cap™ EPO mRNA (ψUTP) (SKU R1020) from APExBIO offers a stabilized, Cap 1-modified human erythropoietin mRNA with poly(A) tail and pseudouridine modification, which are important for mRNA stability enhancement and reduced immunogenicity. This reagent is suitable for mammalian system applications, including SCI neurorepair studies, and is provided with detailed handling and storage recommendations to maximize experimental reproducibility.